TOYOCHEM and FunPep Signed Joint Research Agreement for transdermal patches development of Antibody-Inducing Peptides

This page has been translated using AI.

TOYOCHEM CO., LTD. (President and Representative Director Yasushi Ariyoshi, Chuo-ku, Tokyo) of artience group and FunPep Co., Ltd. (President and Representative Director Toshimi Miyoshi, Ibaraki City, Osaka) are pleased to announce that they have signed a joint research agreement for the transdermal patches development of antibody-inducing peptides.

Antibody-induced peptide are peptide therapeutic vaccines that induce antibody production against target proteins in the patient's body to achieve therapeutic effects.
FunPep is strengthening its research and development pipeline by leveraging antibody-derived peptides drug discovery platform technology, which strengthens its functional peptide 'AJP001' by creating candidate compounds for antibody-induced peptides targeting various proteins.
TOYOCHEM plays a core role in artience group 's polymer and coatings-related businesses, focusing on the medical healthcare field and working on the development of transdermal patches, pressure sensitive adhesives, and biocompatible polymers. transdermal patches operates a CDMO business, conducting contract research and manufacturing with many pharmaceutical companies. By integrating formulation design, polymer development, and coatings technologies, we aim to realize a "safe and skin-friendly transdermal patches."

In this joint research, the goal is to develop a transdermal patches next-generation formulation technology that is less invasive than injectables, offering superior convenience and safety. FunPep will conduct efficacy and safety evaluations in animal studies, while TOYOCHEM plans to study the transdermal absorption of peptides.

About TOYOCHEM 's Transdermal Patches Business

TOYOCHEM contributes to improving patients' quality of life (QOL) in the pharmaceutical field through the development and manufacturing of transdermal patches (TDDS formulations). transdermal patches, which allows continuous delivery of active ingredients through the skin by applying it to the body, offers advantages not found in other dosage forms, such as ease of administration, stable drug administration, and visibility of medication status.
Aiming to realize a "safe and skin-friendly transdermal absorption formulation," our manufacturing and research and development base has been transferred to the Moriyama Plant in Shiga Prefecture, strengthening our structure as a CDMO company. Additionally, by promoting open innovation through enhanced collaboration with academia and external partners, we are accelerating the development of next-generation transdermal absorption formulations.

transdermal patches (TDDS Formulation)
https://www. artiencegroup.com/ja/products/medical-bio/transdermal-medicine/

About FunPep Co., Ltd.

FunPep Co., Ltd. is a venture company originating from Osaka University that possesses proprietary peptide technology. We are mainly engaged in the development of next-generation vaccines called "antibody-inducing peptides" targeting skin diseases and hay fever using functional peptides with immune-boosting functions, as well as functional peptides targeting skin ulcers. Furthermore, we are advancing product development not only in the pharmaceutical business but also in healthcare and cosmetics, aiming to provide a vibrant lifestyle through peptides to the world. For more details, please refer to the website (https://www.funpep.co.jp/).